NeurAxis (NASDAQ:NRXS – Get Free Report) and ENDRA Life Sciences (NASDAQ:NDRA – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends and risk.
Profitability
This table compares NeurAxis and ENDRA Life Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| NeurAxis | -492.76% | N/A | -641.25% |
| ENDRA Life Sciences | N/A | -127.39% | -103.77% |
Earnings and Valuation
This table compares NeurAxis and ENDRA Life Sciences”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| NeurAxis | $2.46 million | 8.82 | -$14.63 million | ($1.84) | -1.69 |
| ENDRA Life Sciences | N/A | N/A | -$10.06 million | ($901.15) | -0.01 |
Risk & Volatility
NeurAxis has a beta of 4.2, indicating that its stock price is 320% more volatile than the S&P 500. Comparatively, ENDRA Life Sciences has a beta of 0.52, indicating that its stock price is 48% less volatile than the S&P 500.
Insider & Institutional Ownership
11.8% of NeurAxis shares are owned by institutional investors. Comparatively, 1.2% of ENDRA Life Sciences shares are owned by institutional investors. 15.2% of NeurAxis shares are owned by company insiders. Comparatively, 0.0% of ENDRA Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Analyst Recommendations
This is a summary of recent ratings and price targets for NeurAxis and ENDRA Life Sciences, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| NeurAxis | 0 | 0 | 0 | 0 | 0.00 |
| ENDRA Life Sciences | 0 | 0 | 1 | 0 | 3.00 |
ENDRA Life Sciences has a consensus price target of $700,000.00, indicating a potential upside of 12,433,292.54%. Given ENDRA Life Sciences’ stronger consensus rating and higher possible upside, analysts clearly believe ENDRA Life Sciences is more favorable than NeurAxis.
Summary
ENDRA Life Sciences beats NeurAxis on 7 of the 13 factors compared between the two stocks.
About NeurAxis
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome. The company sells its products to healthcare companies, including hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.
About ENDRA Life Sciences
ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. It has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.
Receive News & Ratings for NeurAxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeurAxis and related companies with MarketBeat.com's FREE daily email newsletter.
